Full Press Release Details
Theranostics Receives Positive Recommendation from
Data Safety and Monitoring Committee (DSMC) to Accelerate
177Lu-RAD202 Phase 1 HEAT'
Dose Escalation Clinical Trial
1 study to progress to the next dose level of 75mCi in patients with HER2+ advanced solid tumors, instead of the protocol-planned dose
Australia - 1 October 2025 - Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"),
a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical
need, today announced that it has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance
its clinical-stage radiotherapeutic asset, 177Lu-RAD202 (RAD202), to the next dose level of 75mCi in the Phase 1 HEAT' clinical
trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors. The DSMC is a multidisciplinary
committee that conducts detailed reviews of study data, discusses potential safety events and provides recommendations regarding trial
are encouraged by the rapid progress of the Phase 1 HEAT' trial of RAD202 as it underscores the strong interest in new,
effective therapeutic options to treat HER2-positive advanced and metastatic cancers an area of high unmet medical need" said Riccardo
Canevari, CEO and Managing Director of Radiopharm Theranostics. "With initial dosing in June and the swift completion of the first
cohort, the DSMC's recommendation to advance to a higher dose level marks an important step toward identifying the optimal Phase
2 dose and the recognition of very encouraging initial safety signals. Each cohort brings us closer to confirming RAD202's safety
profile and to demonstrating its potential to offer a new treatment option for patients with HER2-positive advanced solid tumors. We
remain on track to share data from the first two cohorts by year-end 2025."
DSMC reviewed the first cohort of patients treated with 30mCi of Lu177-RAD202 and confirmed there was positive safety, pharmacokinetic,
and biodistribution data and agreed that the study may continue without modifications and accelerate to the second cohort of patients
at 75mCi of Lu177-RAD202. The second cohort of patients is expected to be enrolled by Q4 2025.
Phase 1 HEAT' study is currently being conducted at clinical centers across Australia.
is a proprietary single domain monoclonal antibody (sdAb) that targets the Human Epidermal Growth Factor Receptor 2 (HER2)-positive expression
in advanced solid tumors. HER2 is overexpressed in breast cancer and several other solid tumors and represents a validated target in
oncology. In a previous diagnostic study of ten HER2-positive breast cancer patients, RAD202 demonstrated clinical proof-of-concept and
had positive safety and biodistribution.
Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
Radiopharm Theranostics
Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products
for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX).
The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal
antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers
including lung, breast, and brain. Learn more at radiopharmtheranostics.com.
on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.
CEO & Managing Director
AQ (formerly Stern IR)
Radiopharm Theranostics:
InvestorHub - https://investorhub.radiopharmtheranostics.com/
Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia